German vaccine manufacturer BioNTech saw profits fall dramatically in 2023, as revenue from Covid-19 vaccines dropped sharply and the company invested in research on new cancer drugs. BioNTech, based in the western German city of Mainz, reported net profits in 2023 of €930.3 million ($1.01 billion) on Wednesday. That was a major drop from the €9.4 billion in profits the company reported in 2022. BioNTech plans to launch its first cancer drug on the market in 2026, chief executive Uğur Şahin announced on Wednesday during a presentation of the company’s financial results. He said that the compan…